[Understanding current therapies in metastatic melanoma].

Rev Med Chil

Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Published: November 2016

Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872016001100011DOI Listing

Publication Analysis

Top Keywords

anti-programmed cell
8
cell death
8
death protein
8
[understanding current
4
therapies
4
current therapies
4
therapies metastatic
4
metastatic melanoma]
4
melanoma] cutaneous
4
cutaneous melanoma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!